Zealand Pharma A/S Stock price

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 15:59:31 27/02/2024 GMT 5-day change 1st Jan Change
620 DKK -4.39% Intraday chart for Zealand Pharma A/S +28.74% +66.13%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site

Financials

Sales 2023 * 347M 50.48M 3.98B Sales 2024 * 1.39B 202M 15.92B Capitalization 40.29B 5.87B 462B
Net income 2023 * -556M -80.93M -6.38B Net income 2024 * 325M 47.31M 3.73B EV / Sales 2023 * 111 x
Net cash position 2023 * 1.75B 255M 20.1B Net cash position 2024 * 3.48B 506M 39.91B EV / Sales 2024 * 26.5 x
P/E ratio 2023 *
-50.6 x
P/E ratio 2024 *
123 x
Employees 249
Yield 2023 *
-
Yield 2024 *
-
Free-Float 93.22%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.16%
1 week+27.41%
Current month+31.30%
1 month+30.20%
3 months+93.63%
6 months+135.56%
Current year+66.13%
More quotes
1 week
457.60
Extreme 457.6
651.50
1 month
431.00
Extreme 431
651.50
Current year
342.20
Extreme 342.2
651.50
1 year
205.60
Extreme 205.6
651.50
3 years
69.55
Extreme 69.55
651.50
5 years
69.55
Extreme 69.55
651.50
10 years
58.00
Extreme 58
651.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 31/12/09
Director of Finance/CFO - 31/10/22
Chief Tech/Sci/R&D Officer - 03/09/20
Members of the board TitleAgeSince
Director/Board Member 66 03/04/19
Chairman 69 31/12/14
Director/Board Member 68 18/04/18
More insiders
Date Price Change Volume
27/02/24 620 -4.39% 1 244 514
26/02/24 648.5 +35.67% 1,579,502
23/02/24 478 +1.10% 176,285
22/02/24 472.8 +2.43% 349,608
21/02/24 461.6 -5.14% 528,743

Delayed Quote Nasdaq Copenhagen, February 27, 2024 at 03:59 pm

More quotes
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
648.5 DKK
Average target price
492.5 DKK
Spread / Average Target
-24.06%
Consensus
  1. Stock
  2. Equities
  3. Stock Zealand Pharma A/S - Nasdaq Copenhagen
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW